Which hedge funds own TAK? TAKEDA PHARMACEUTICAL CO LTD, Q2 2026 13F holders
23 tracked hedge funds disclosed a position in TAK (TAKEDA PHARMACEUTICAL CO LTD) in their Q2 2026 13F filings, worth $345.0m in total. The largest holder by portfolio weight is PFM Health Sciences, LP at 0.6% of its book. 12 opened a new position this quarter: PFM Health Sciences, LP, Entropy Technologies, LP, Qube Research & Technologies Ltd, Graham Capital Management, L.P.. 4 exited: Corient IA LP, Aquatic Capital Management LLC, Trexquant Investment LP.
- 23
- Holders Tracked managers whose filing for the quarter reports a long equity position in the security.
- 12
- New this quarter Holders whose previous filing (at most two quarters earlier) did not report the security.
- 4
- Exited this quarter Tracked managers whose previous filing reported the security and whose filing for the quarter does not.
- $70.4m
- Inflow, new holders Combined value of the positions the new holders reported for the quarter.
- $8.4m
- Outflow, exits Combined value the exiting managers reported for the security in their previous filing.
- $345m
- Combined value Sum of the holders' reported positions in the security.
- 1.9%
- Share of managers holding Holders as a share of tracked managers filing for that quarter. Comparable across the 2024 coverage expansion, where the raw holder count is not.
Holders, Q2 2026
Exited since the previous filing
| Corient IA LP | 0.3% | $276k |
| Aquatic Capital Management LLC | 0.08% | $2.8m |
| Trexquant Investment LP | 0.03% | $4.2m |
| Squarepoint Ops LLC | 0.0% | $1.0m |
Ownership over time
Who discovered TAK first? Beta
| Glenview Capital Management, LLC high conviction | Q1 2019 | 0.0 pts |
| Hunting Hill Global Capital, LLC | Q1 2019 | 0.0 pts |
| Redwood Capital Management, LLC | Q1 2019 | −0.1 pts |
| Melqart Asset Management (UK) Ltd | Q1 2019 | −0.1 pts |
| Athos Capital Ltd | Q1 2019 | −0.3 pts |
| GMT Capital Corp | Q3 2019 | −0.3 pts |
| MFN Partners Management, LP | Q1 2019 | −0.4 pts |
| NINE MASTS CAPITAL Ltd high conviction | Q1 2019 | −0.9 pts |
Split-adjusted quarter-end prices, excluding dividends. They describe the stock while each manager held it, not the return it earned.